Us Bancorp \De\ Legend Biotech Corp Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Legend Biotech Corp stock. As of the latest transaction made, Us Bancorp \De\ holds 4,812 shares of LEGN stock, worth $175,253. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,812

Previous 4,976 3.3%

Holding current value

$175,253

Previous $242,000 35.54%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$32.49 - $50.28 $5,328 - $8,245	-164 Reduced 3.3%	4,812 $156,000
Q3 2024 Oct 28, 2024	SELL	$43.55 - $59.88 $273,450 - $375,986	-6,279 Reduced 55.79%	4,976 $242,000
Q2 2024 Aug 06, 2024	BUY	$39.5 - $57.22 $174,590 - $252,912	4,420 Added 64.67%	11,255 $498,000
Q1 2024 May 07, 2024	BUY	$55.06 - $69.99 $16,132 - $20,507	293 Added 4.48%	6,835 $383,000
Q4 2023 Feb 09, 2024	SELL	$57.25 - $69.74 $117,763 - $143,455	-2,057 Reduced 23.92%	6,542 $393,000
Q3 2023 Nov 03, 2023	SELL	$63.16 - $76.5 $26,590 - $32,206	-421 Reduced 4.67%	8,599 $577,000
Q2 2023 Aug 09, 2023	SELL	$46.28 - $75.01 $224,874 - $364,473	-4,859 Reduced 35.01%	9,020 $622,000
Q1 2023 May 09, 2023	BUY	$43.42 - $57.37 $35,213 - $46,527	811 Added 6.21%	13,879 $669,000
Q4 2022 Feb 13, 2023	BUY	$38.8 - $55.46 $493,070 - $704,785	12,708 Added 3530.0%	13,068 $652,000
Q3 2022 Oct 27, 2022	BUY	$38.15 - $57.1 $4,501 - $6,737	118 Added 48.76%	360 $15,000
Q1 2022 May 11, 2022	BUY	$31.02 - $48.18 $4,963 - $7,708	160 Added 195.12%	242 $9,000
Q4 2021 Feb 11, 2022	SELL	$41.14 - $56.98 $10,285 - $14,245	-250 Reduced 75.3%	82 $4,000
Q3 2021 Nov 10, 2021	BUY	$35.31 - $50.56 $11,722 - $16,785	332 New	332 $17,000

Others Institutions Holding LEGN

# of Institutions

230

Shares Held

82.6M

Call Options Held

233K

Put Options Held

339K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.1B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account